Table of Content

1. Key Insights

2. Cutaneous Lupus Erythematosus (CLE): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Cutaneous Lupus Erythematosus (CLE) in 2017
2.2. Total Market Share (%) Distribution of Cutaneous Lupus Erythematosus (CLE) in 2028

3. Disease Background and Overview: Cutaneous Lupus Erythematosus (CLE)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of Cutaneous Lupus Erythematosus
3.4. Etiology
3.5. Genetic Bases of Cutaneous Lupus Erythematosus
3.6. Pathogenesis
3.7. Diagnosis
3.7.1. Diagnosis criteria for the sub-types of CLE
3.7.2. Diagnosis Guidelines
3.7.3. S2k - European Dermatology Forum (EDF) Guideline on Diagnosis and Monitoring in Cutaneous Lupus Erythematosus
3.7.4. Differential Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent cases of Cutaneous Lupus Erythematosus in 7MM
4.3. United States
4.3.1. Assumptions and Rationale
4.3.2. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.3. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.4. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.5. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.3.6. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in the US
4.4. EU-5
4.4.1. Assumptions and Rationale
4.5. Germany
4.5.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.5.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Germany
4.6. France
4.6.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.6.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in France
4.7. Italy
4.7.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.7.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Italy
4.8. Spain
4.8.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.8.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Spain
4.9. United Kingdom
4.9.1. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.2. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.3. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.4. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.9.5. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in the UK
4.10. Japan
4.10.1. Assumptions and Rationale
4.10.2. Total Prevalent cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.3. Gender Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.4. Diagnosed Cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.5. Type Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan
4.10.6. Severity Specific cases of Cutaneous Lupus Erythematosus (CLE) in Japan

5. Treatment and Management of Cutaneous lupus erythematosus
5.1. S2k Guideline for Treatment of Cutaneous Lupus Erythematosus
5.2. Treatment Benefits Based on the Oxford Centre for Evidence-based Medicine Criteria

6. Unmet Needs

7. Emerging Drugs
7.1. Key Cross Competition
7.2. BIIB059: Biogen
7.2.1. Drug Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Etanercept: Pfizer
7.3.1. Drug Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. Filgotinib: Galapagos NV /Gilead Sciences
7.4.1. Drug Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Product Profile
7.5. GS-9876: Gilead Sciences
7.6. Drug Description
7.7. Other Developmental Activities
7.8. Clinical Development
7.9. Product Profile
7.10. Delgocitinib: LEO Pharma/ Japan Tobacco
7.10.1. Product Description
7.10.2. Other Developmental Activities
7.10.3. Clinical Development
7.10.4. Product Profile
7.11. VIB7734: VIELABIO
7.11.1. Drug Description
7.11.2. Other Developmental Activities
7.11.3. Clinical Development
7.11.4. Product Profile

8. Cutaneous Lupus Erythematosus (CLE): Market Analysis
8.1. Key Findings
8.2. Market Size of Cutaneous Lupus Erythematosus (CLE) in 7MM
8.3. US: Market Outlook
8.3.1. US Market Size
8.3.2. Market size of Cutaneous Lupus Erythematosus (CLE) in the US
8.3.3. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.4. EU-5: Market outlook
8.5. Germany
8.5.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Germany
8.5.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.6. France
8.6.1. Market size of Cutaneous Lupus Erythematosus (CLE) in France
8.6.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.7. Italy
8.7.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Italy
8.7.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.8. Spain
8.8.1. Market size of Cutaneous Lupus Erythematosus (CLE) in Spain
8.8.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.9. United Kingdom
8.9.1. Market size Cutaneous Lupus Erythematosus (CLE) in the UK
8.9.2. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies
8.10. Japan: Market Outlook
8.10.1. Japan Market Size
8.10.2. Market size of Cutaneous Lupus Erythematosus (CLE) in Japan
8.10.3. Market size of Cutaneous Lupus Erythematosus (CLE) by Therapies

9. Market Drivers

10. Market Barriers

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight



List of Figures


Figure 1: Common symptoms of Lupus
Figure 2: The inflammatory cascades of cutaneous lupus
Figure 3: Summary of CLE pathogenesis
Figure 4: The autoimmune response of cutaneous lupus
Figure 5: Total Prevalent cases of CLE in 7MM (2017-2028)
Figure 6: Total Prevalent Cases of CLE in the US (2017-2028)
Figure 7: Gender Specific Cases of CLE in the US (2017-2028)
Figure 8: Diagnosed Cases of CLE in the US (2017-2028)
Figure 9: Type Specific Cases of CLE in the US (2017-2028)
Figure 10: Severity Specific Cases of CLE in the US (2017-2028)
Figure 11: Total Prevalent Cases of CLE in Germany (2017-2028)
Figure 12: Gender Specific Cases of CLE in Germany (2017-2028)
Figure 13: Diagnosed Cases of CLE in Germany (2017-2028)
Figure 14: Type Specific Cases of CLE in Germany (2017-2028)
Figure 15: Severity Specific Cases of CLE in Germany (2017-2028)
Figure 16: Total Prevalent Cases of CLE in France (2017-2028)
Figure 17: Gender Specific Cases of CLE in France (2017-2028)
Figure 18: Diagnosed Cases of CLE in France (2017-2028)
Figure 19: Type Specific Cases of CLE in France (2017-2028)
Figure 20: Severity Specific Cases of CLE in France (2017-2028)
Figure 21: Total Prevalent Cases of CLE in Italy (2017-2028)
Figure 22: Gender Specific Cases of CLE in Italy (2017-2028)
Figure 23: Diagnosed Cases of CLE in Italy (2017-2028)
Figure 24: Type Specific Cases of CLE in Italy (2017-2028)
Figure 25: Severity Specific Cases of CLE in Italy (2017-2028)
Figure 26: Total Prevalent Cases of CLE in Spain (2017-2028)
Figure 27: Gender Specific Cases of CLE in Spain (2017-2028)
Figure 28: Diagnosed Cases of CLE in Spain (2017-2028)
Figure 29: Type Specific Cases of CLE in Spain (2017-2028)
Figure 30: Severity Specific Cases of CLE in Spain (2017-2028)
Figure 31: Total Prevalent Cases of CLE in the UK (2017-2028)
Figure 32: Gender Specific Cases of CLE in the UK (2017-2028)
Figure 33: Diagnosed Cases of CLE in the UK (2017-2028)
Figure 34: Type Specific Cases of CLE in the UK (2017-2028)
Figure 35: Severity Specific Cases of CLE in the UK (2017-2028)
Figure 36: Total Prevalent Cases of CLE in Japan (2017-2028)
Figure 37: Gender Specific Cases of CLE in Japan (2017-2028)
Figure 38: Diagnosed Cases of CLE in Japan (2017-2028)
Figure 39: Type Specific Cases of CLE in Japan (2017-2028)
Figure 40: Severity Specific Cases of CLE in Japan (2017-2028)
Figure 41: Subtypes of cutaneous lupus erythematosus (CLE)
Figure 42: Recommended treatments for the CLE
Figure 43: Topical Therapies for the treatment of CLE
Figure 44: Algorithm for cutaneous lupus erythematosus treatment
Figure 45: Unmet Needs
Figure 46: Market Size of CLE in 7MM in USD Million (2017-2028)
Figure 47: Market size of CLE in the US (2017-2028)
Figure 48: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 49: Market size of CLE in Germany (2017-2028)
Figure 50: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 51: Market size of CLE in France (2017-2028)
Figure 52: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 53: Market size of CLE in Italy (2017-2028)
Figure 54: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 55: Market size of CLE in Spain (2017-2028)
Figure 56: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 57: Market size of CLE in the UK (2017-2028)
Figure 58: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 59: Market size of CLE in Japan (2017-2028)
Figure 60: Market Size of CLE by Therapies in USD Million (2017-2028)
Figure 61: Market Drivers
Figure 62: Market Barriers

 

List of Tables


Table 1: Types of cutaneous lupus erythematosus (CLE)
Table 2: Histopathology of cutaneous LE lesions
Table 3: Laboratory tests in cutaneous lupus erythematosus
Table 4: Technical investigation
Table 5: Diagnostic criteria for discoid lupus erythematosus
Table 6: Diagnostic criteria for Chilblain Lupus
Table 7: Diagnostic criteria for Lupus Erythematosus Tumidus
Table 8: Diagnostic criteria for lupus panniculitis
Table 9: Diagnostic criteria for subacute cutaneous lupus erythematosus
Table 10: Diagnostic criteria for acute cutaneous lupus erythematosus
Table 11: Recommendations
Table 12: ACR Criteria/SLICC Criteria Recommendations
Table 13: Histology and Direct immunofluorescence Recommendations
Table 14: Photoprovocation Recommendations
Table 15: Laboratory Diagnostics Recommendations
Table 16: Differential diagnoses of cutaneous lupus erythematosus
Table 17: Total Prevalent cases of CLE in 7MM (2017-2028)
Table 18: Total Prevalent Cases of CLE in the US (2017-2028)
Table 19: Gender Specific Prevalent Cases of CLE in the US (2017-2028)
Table 20: Diagnosed Cases of CLE in the US (2017-2028)
Table 21: Type Specific Prevalent Cases of CLE in the US (2017-2028)
Table 22: Severity Specific Prevalent Cases of CLE in the US (2017-2028)
Table 23: Total Prevalent Cases of CLE in Germany (2017-2028)
Table 24: Gender Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 25: Diagnosed Cases of CLE in Germany (2017-2028)
Table 26: Type Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 27: Severity Specific Prevalent Cases of CLE in Germany (2017-2028)
Table 28: Total Prevalent Cases of CLE in France (2017-2028)
Table 29: Gender Specific Prevalent Cases of CLE in France (2017-2028)
Table 30: Diagnosed Cases of CLE in France (2017-2028)
Table 31: Type Specific Prevalent Cases of CLE in France (2017-2028)
Table 32: Severity Specific Prevalent Cases of CLE in France (2017-2028)
Table 33: Total Prevalent Cases of CLE in Italy (2017-2028)
Table 34: Gender Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 35: Diagnosed Cases of CLE in Italy (2017-2028)
Table 36: Type Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 37: Severity Specific Prevalent Cases of CLE in Italy (2017-2028)
Table 38: Total Prevalent Cases of CLE in Spain (2017-2028)
Table 39: Gender Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 40: Diagnosed Cases of CLE in Spain (2017-2028)
Table 41: Type Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 42: Severity Specific Prevalent Cases of CLE in Spain (2017-2028)
Table 43: Total Prevalent Cases of CLE in the UK (2017-2028)
Table 44: Gender Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 45: Diagnosed Cases of CLE in the UK (2017-2028)
Table 46: Type Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 47: Severity Specific Prevalent Cases of CLE in the UK (2017-2028)
Table 48: Total Prevalent Cases of CLE in Japan (2017-2028)
Table 49: Gender Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 50: Diagnosed Cases of CLE in Japan (2017-2028)
Table 51: Type Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 52: Severity Specific Prevalent Cases of CLE in Japan (2017-2028)
Table 53: Preventive Measures and Risk Factors Recommendations
Table 54: Pregnancy or Hormonal Therapy Recommendations
Table 55: Topical Treatment Recommendations
Table 56: UV Treatment, Cryotherapy, and Lasers Recommendations
Table 57: Oxford Centre for Evidence-Based Medicine 2011 Treatment Benefit Levels of Evidence
Table 58: Combination therapy in cutaneous lupus erythematous
Table 59: Therapies for cutaneous lupus erythematosus and the levels of evidence supporting therapeutic benefit according to the Oxford Centre for Evidence-Based Medicine Criteria
Table 60: Summary of cutaneous lupus erythematosus therapeutic interventions
Table 61: Emerging Drugs Analysis
Table 62: BIIB059, Clinical Trial Description, 2019
Table 63: Etanercept, Clinical Trial Description, 2019
Table 64: Filgotinib, Clinical Trial Description, 2019
Table 65: GS-9876, Clinical Trial Description, 2019
Table 66: Delgocitinib, Clinical Trial Description, 2019
Table 67: VIB7734, Clinical Trial Description, 2019
Table 68: Market Size of CLE in 7MM in USD Million (2017-2028)
Table 69: Market size of CLE in the US (2017-2028)
Table 70: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 71: Market size of CLE in Germany (2017-2028)
Table 72: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 73: Market size of CLE in France (2017-2028)
Table 74: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 75: Market size of CLE in Italy (2017-2028)
Table 76: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 77: Market size of cutaneous lupus erythematosus (CLE) in Spain (2017-2028)
Table 78: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 79: Market size of CLE in the UK (2017-2028)
Table 80: Market Size of CLE by Therapies in USD Million (2017-2028)
Table 81: Market size of CLE in Japan (2017-2028)
Table 82: Market Size of CLE by Therapies in USD Million (2017-2028)